Cisplatin is the prototype platinum coordination complex classified as an alkylating agent and used intravenously in the treatment of several forms of cancer. Cisplatin has been associated with a low rate of serum enzyme elevations and with rare cases of clinically apparent, acute liver injury.
Cisplatin is a chemotherapy drug used to treat testicular, ovarian, bladder, head and neck, lung and cervical cancer. It may also be used to treat other cancers. It is best to read this information with our general information about chemotherapy and the type of cancer you have.
Cisplatin, cisplatinum, or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Mechanism of action
Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.
Cisplatin is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands – directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result – disruption of DNA function and cell death.
Indications
- For the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer.
- Mantle cell lymphoma that has relapsed (come back) or is refractory (does not respond to treatment).
- Precursor B lymphoblastic leukemia (a type of acute lymphoblastic leukemia) has relapsed or is refractory.
- Advanced Ovarian Cancer
- Ovarian Cancer Metastatic
- Advanced Bladder cancer
- Advanced Testicular cancer
- Metastatic Testicular cancer
Use in Cancer
Cisplatin is approved to be used alone or with other drugs to treat:
- Bladder cancer. It is used alone in patients with advanced cancer that cannot be treated with other therapies, such as surgery or radiation therapy.
- Ovarian cancer has spread to other parts of the body. It is used with other drugs in patients who have already had surgery or radiation therapy. It is used alone in patients whose cancer has not gotten better with standard chemotherapy and who have not received previous cisplatin.
- Testicular cancer has spread to other parts of the body. It is used with other drugs in patients who have already had surgery or radiation therapy.
Cisplatin is also being studied in the treatment of other types of cancer.
Contraindications
- are allergic to cisplatin, any platinum-containing compounds, or any ingredients of the medication
- have hearing impairment
- have reduced bone marrow function (e.g. low white cells)
- have reduced kidney function
- Severe hypersensitivity to cisplatin or platinum compounds would preclude its administration; cisplatin is contraindicated in patients who have had severe hypersensitivity reactions, and rechallenge is not a recommendation.
- Cisplatin has been shown to cross the placenta and may cause fetal harm.[rx][rx] Women of reproductive age should use reliable contraception during treatment and up to a year from the final treatment date.
- Cisplatin is also present in the breast milk of lactating women on a cisplatin regimen.[rx] Breastfeeding is not recommended during treatment.[rx] If hypersensitivity occurs, the provider should discontinue cisplatin immediately.[rx]
- a bad infection
- acute leukemia
- low amount of magnesium in the blood
- low amount of calcium in the blood
- low amount of sodium in the blood
- low amount of potassium in the blood
- hemolytic uremic syndrome, a condition that affects the kidney and the blood
- anemia
- decreased blood platelets
- low levels of white blood cells
- a painful condition that affects the nerves in the legs and arms called peripheral neuropathy
- sudden blindness and pain upon moving the eye
- ototoxicity, damage to the inner ear that affects hearing or balance
- hearing loss
- a heart attack
- a clot in the lung
- a stroke
- inflammation of blood vessels in the brain or spinal cord
- Raynaud’s phenomenon, a condition where blood vessels constrict too much with coldness or stress
- blood clot in a deep vein of the extremities
- thrombotic thrombocytopenic purpura, a type of blood disorder
- decreased kidney function
- vomiting
- amount of uric acid in the blood
- pregnancy
- a patient who is producing milk and breastfeeding
- TPMT poor metabolizer
- a type of brain disorder called posterior reversible encephalopathy syndrome
- a clot in the aorta
- kidney disease with likely reduction in kidney function
Dosage
Strengths: 50 mg; 10 mg; 1 mg/mL
Testicular Cancer
- 20 mg/m2 by slow IV infusion daily for 5 days per cycle in combination with other approved chemotherapeutic agents
Ovarian Cancer
- 75 to 100 mg/m2 by slow IV infusion once every 3 to 4 weeks on Day 1
Bladder Cancer
- 50 to 70 mg/m2 by slow IV infusion once every 3 to 4 weeks; for heavily pretreated patients, an initial dose of 50 mg/m2 by slow IV infusion once every 4 weeks is recommended
FDA Approved Adult Dosing Regimens
- Advanced testicular cancer: 20 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle.
- Advanced bladder cancer: 50 to 70 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle.
- Advanced ovarian cancer: 100 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle.
Cisplatin can be used as monotherapy or as part of a multi-drug regimen. Patients should have proper hydration while monitoring urine output before, during, and for 24 hours following administration.
Renal Dose Adjustments
- Creatinine clearance between 10 and 50: decrease dose by 25%
- Creatinine clearance below 10: decrease dose by 50%
- Hemodialysis: Decrease the dose by 50% with no supplement; administer after dialysis on dialysis days with no supplement
- Peritoneal dialysis: Decrease the dose by 50% with no supplement
Side Effects
The Most Common
- nausea
- vomiting
- diarrhea
- hair loss
- loss in ability to taste food
- hiccups
- dry mouth, dark urine, decreased sweating, dry skin, and other signs of dehydration
- swelling, pain, redness, or burning at the injection site
- pain, burning, or tingling in the hands or feet
- muscle cramps
- difficulty walking
- feeling of an electric-like shock when you bend your neck forward
- seizures
- sudden changes in vision, including color vision
- loss of vision
- eye pain
- chest pain or pressure
- fever, sore throat, chills, or other signs of infection
- unusual bleeding or bruising
- black and tarry stools
- red blood in stools
- bloody vomit
- vomited material that looks like coffee grounds
More Common
- loss of appetite
- nausea and vomiting
- taste disturbances
- temporary hair loss
- blurred vision
- diarrhea
- difficulty in the ability to distinguish colors
- difficulty walking
- hearing difficulties
- loss of balance
- loss of reflexes
- muscle cramps
- numbness or tingling in fingers or toes
- ringing in ears
- severe nausea and vomiting
- unusual tiredness or weakness
- walking problems
Rare
- pain, redness, or swelling at the site of injection
- seizures
- signs of a serious allergic reaction (difficulty breathing, wheezing, swelling of the face and throat, increased heart rate, dizziness)
- signs of bleeding (e.g., unusual bruising or bleeding, pinpoint red spots on the skin, black tarry stools, bloody nose, blood in urine, coughing blood, cuts that don’t stop bleeding)
- signs of infection (symptoms may include fever or chills, sore throat, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, painful or difficult urination, or listlessness)
- pain, burning, redness at the injection site,
- numbness, tingling, coldness or blue discoloration of the hands or feet,
- pain, redness, swelling of arms or legs,
- loss of reflexes,
- loss of balanced,
- trouble walking,
- muscle cramps or spasms,
- weakness,
- neck or back pain,
- mouth or tongue sores,
- joint pain,
Drug Interaction
| DRUG | INTERACTION |
|---|---|
| Abacavir | Abacavir may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Abatacept | The risk or severity of adverse effects can be increased when Cisplatin is combined with Abatacept. |
| Abciximab | The risk or severity of bleeding can be increased when Abciximab is combined with Cisplatin. |
| Acebutolol | Cisplatin may increase the bradycardic activities of Acebutolol. |
| Aceclofenac | Aceclofenac may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Acemetacin | Acemetacin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Acenocoumarol is combined with Cisplatin. |
| Acetaminophen | Acetaminophen may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Acetazolamide | Acetazolamide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Acetylcholine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Acetylcholine. |
| Acetyldigitoxin | Acetyldigitoxin may decrease the cardiotoxic activities of Cisplatin. |
| Acetylsalicylic acid | Acetylsalicylic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Aclidinium | Aclidinium may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Acrivastine | Acrivastine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Acyclovir | Acyclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Cisplatin. |
| Adefovir dipivoxil | Adefovir dipivoxil may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Adenovirus | The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Cisplatin. |
| Albutrepenonacog alfa | Albutrepenonacog alfa may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Alclofenac | Alclofenac may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cisplatin. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Cisplatin. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cisplatin. |
| Alendronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Alendronic acid. |
| Allogeneic processed | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Cisplatin. |
| Allopurinol | The risk or severity of adverse effects can be increased when Allopurinol is combined with Cisplatin. |
| Almasilate | Almasilate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Almotriptan | Almotriptan may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Alogliptin | Alogliptin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Alprazolam | Alprazolam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Alteplase | The risk or severity of bleeding can be increased when Alteplase is combined with Cisplatin. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Cisplatin. |
| Amantadine | The serum concentration of Cisplatin can be increased when it is combined with Amantadine. |
| Amifampridine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Amifampridine. |
| Amikacin | Amikacin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Amiloride | The serum concentration of Cisplatin can be increased when it is combined with Amiloride. |
| Aminohippuric acid | The serum concentration of Cisplatin can be increased when it is combined with Aminohippuric acid. |
| Aminophenazone | Aminophenazone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Amiodarone | The serum concentration of Cisplatin can be increased when it is combined with Amiodarone. |
| Amitriptyline | Amitriptyline may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ammonium chloride | Ammonium chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Amobarbital | The therapeutic efficacy of Amobarbital can be decreased when used in combination with Cisplatin. |
| Amoxapine | The therapeutic efficacy of Amoxapine can be decreased when used in combination with Cisplatin. |
| Amoxicillin | Amoxicillin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Amphetamine | Amphetamine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Amphotericin B | Amphotericin B may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ampicillin | Ampicillin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Amrinone | Amrinone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Cisplatin. |
| Anagrelide | The risk or severity of bleeding can be increased when Anagrelide is combined with Cisplatin. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Cisplatin. |
| Anastrozole | The risk or severity of cardiotoxicity can be increased when Cisplatin is combined with Anastrozole. |
| Ancestim | Ancestim may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ancrod | The risk or severity of bleeding can be increased when Ancrod is combined with Cisplatin. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Anifrolumab. |
| Belatacept | The risk or severity of adverse effects can be increased when Cisplatin is combined with Belatacept. |
| Belimumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Belimumab. |
| Belinostat | The risk or severity of adverse effects can be increased when Cisplatin is combined with Belinostat. |
| Belladonna | The therapeutic efficacy of Belladonna can be decreased when used in combination with Cisplatin. |
| Belumosudil | The risk or severity of adverse effects can be increased when Cisplatin is combined with Belumosudil. |
| Bemiparin | The risk or severity of bleeding can be increased when Bemiparin is combined with Cisplatin. |
| Bendamustine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Bendamustine. |
| Bendroflumethiazide | Bendroflumethiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Benorilate | Benorilate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Benoxaprofen | Benoxaprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Benserazide | Benserazide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Benzatropine | Benzatropine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Benznidazole | Benznidazole may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Benzocaine. |
| Benzonatate | Cisplatin may increase the neuromuscular blocking activities of Benzonatate. |
| Benzphetamine | The metabolism of Benzphetamine can be decreased when combined with Cisplatin. |
| Benzthiazide | Benzthiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Benzydamine | Benzydamine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Benzyl alcohol. |
| Bepotastine | Bepotastine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Betamethasone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Betamethasone. |
| Betamethasone phosphate | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Betamethasone phosphate. |
| Betaxolol | Cisplatin may increase the bradycardic activities of Betaxolol. |
| Bethanechol | The risk or severity of adverse effects can be increased when Cisplatin is combined with Bethanechol. |
| Betrixaban | The risk or severity of bleeding can be increased when Betrixaban is combined with Cisplatin. |
| Bevacizumab | The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cisplatin. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Cisplatin. |
| Bicisate | Bicisate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Bimekizumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Bimekizumab. |
| Biperiden | The therapeutic efficacy of Biperiden can be decreased when used in combination with Cisplatin. |
| Bismuth subgallate | Bismuth subgallate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Bisoprolol | Bisoprolol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Bisoxatin | Bisoxatin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Bivalirudin | The risk or severity of bleeding can be increased when Bivalirudin is combined with Cisplatin. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Cisplatin. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Blinatumomab. |
| Bordetella pertussis | The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Cisplatin. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Cisplatin. |
| Bosutinib | The risk or severity of adverse effects can be increased when Cisplatin is combined with Bosutinib. |
| Brentuximab vedotin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Brentuximab vedotin. |
| Brivaracetam | Brivaracetam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Brodalumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Brodalumab. |
| Bromazepam | Bromazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Bromotheophylline | Bromotheophylline may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Brompheniramine | The metabolism of Brompheniramine can be decreased when combined with Cisplatin. |
| Buclizine | The therapeutic efficacy of Buclizine can be decreased when used in combination with Cisplatin. |
| Budesonide | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Budesonide. |
| Bumadizone | Bumadizone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Bumetanide | The risk or severity of ototoxicity and nephrotoxicity can be increased when Bumetanide is combined with Cisplatin. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Bupivacaine. |
| Bupropion | The excretion of Cisplatin can be decreased when combined with Bupropion. |
| Buspirone | Buspirone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Busulfan | The risk or severity of adverse effects can be increased when Cisplatin is combined with Busulfan. |
| Butabarbital | Butabarbital may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Butacaine. |
| Butalbital | The therapeutic efficacy of Butalbital can be decreased when used in combination with Cisplatin. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Butamben. |
| Butobarbital | The therapeutic efficacy of Butobarbital can be decreased when used in combination with Cisplatin. |
| Butylscopolamine | The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Cisplatin. |
| Cabazitaxel | The risk or severity of adverse effects can be increased when Cisplatin is combined with Cabazitaxel. |
| Canagliflozin | Canagliflozin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Canakinumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Canakinumab. |
| Cangrelor | The risk or severity of bleeding can be increased when Cangrelor is combined with Cisplatin. |
| Canrenoic acid | Canrenoic acid may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Capecitabine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Capecitabine. |
| Caplacizumab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Cisplatin. |
| Capreomycin | Capreomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Capsaicin. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Carbamazepine. |
| Carbamoylcholine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Carbamoylcholine. |
| Carbidopa | Carbidopa may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Carboplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Carboplatin. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Cisplatin is combined with Carfilzomib. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Cisplatin. |
| Carprofen | Carprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Carvedilol | Cisplatin may increase the bradycardic activities of Carvedilol. |
| Cefaclor | Cefaclor may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefadroxil | Cefadroxil may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefalotin | Cefalotin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefamandole | Cefamandole may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefapirin | Cefapirin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefazolin | Cefazolin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefdinir | Cefdinir may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefditoren | Cefditoren may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefepime | Cefepime may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefmenoxime | Cefmenoxime may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefmetazole | Cefmetazole may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefonicid | Cefonicid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefoperazone | Cefoperazone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ceforanide | Ceforanide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefotaxime | Cefotaxime may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefotetan | Cefotetan may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefotiam | Cefotiam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefoxitin | Cefoxitin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefpiramide | Cefpiramide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefpirome | Cefpirome may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefpodoxime | Cefpodoxime may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefprozil | Cefprozil may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefradine | Cefradine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ceftazidime | Ceftazidime may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ceftibuten | Ceftibuten may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ceftizoxime | Ceftizoxime may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ceftobiprole | Ceftobiprole may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ceftolozane | Ceftolozane may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ceftriaxone | Ceftriaxone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cefuroxime | Cefuroxime may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Celecoxib | Celecoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Celiprolol | Cisplatin may increase the bradycardic activities of Celiprolol. |
| Cenobamate | The metabolism of Cenobamate can be decreased when combined with Cisplatin. |
| Cephalexin | Cephalexin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cephaloglycin | Cephaloglycin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Certolizumab pegol | The risk or severity of adverse effects can be increased when Cisplatin is combined with Certolizumab pegol. |
| Cetirizine | Cetirizine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cevimeline | Cevimeline may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Chloral hydrate | Chloral hydrate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Cisplatin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Cisplatin. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Chloroprocaine. |
| Chloroquine | Chloroquine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Chlorothiazide | Chlorothiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Chloroxylenol | Chloroxylenol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Chlorpheniramine | The serum concentration of Cisplatin can be increased when it is combined with Chlorpheniramine. |
| Chlorpromazine | Chlorpromazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Chlorpropamide | Chlorpropamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Chlorprothixene | The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Cisplatin. |
| Chlorthalidone | Chlorthalidone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Chlorzoxazone | Chlorzoxazone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Choline | The serum concentration of Cisplatin can be increased when it is combined with Choline. |
| Choline C 11 | Choline C 11 may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Choline magnesium | Choline magnesium trisalicylate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Choline salicylate | The serum concentration of Cisplatin can be increased when it is combined with Choline salicylate. |
| Chondroitin sulfate | Chondroitin sulfate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Chromic chloride | Chromic chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Chromic nitrate | Chromic nitrate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Chromium | Chromium may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Chromium gluconate | Chromium gluconate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Chromium nicotinate | Chromium nicotinate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Chromous sulfate | Chromous sulfate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ciclesonide | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Ciclesonide. |
| Cidofovir | Cidofovir may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cilostazol | Cilostazol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cimetidine | The serum concentration of Cisplatin can be increased when it is combined with Cimetidine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Cinchocaine. |
| Cinnarizine | The metabolism of Cinnarizine can be decreased when combined with Cisplatin. |
| Ciprofloxacin | Ciprofloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Cisapride | The metabolism of Cisapride can be decreased when combined with Cisplatin. |
| Cisatracurium | The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Cisplatin. |
| Cladribine | The risk or severity of adverse effects can be increased when Cladribine is combined with Cisplatin. |
| Clevidipine | Clevidipine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Clidinium | The therapeutic efficacy of Clidinium can be decreased when used in combination with Cisplatin. |
| Clobazam | Clobazam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Clobetasol propionate | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Clobetasol propionate. |
| Clodronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Clodronic acid. |
| Clofarabine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Clofarabine. |
| Clomipramine | Clomipramine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Clonazepam | Clonazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Clopidogrel | The serum concentration of Cisplatin can be increased when it is combined with Clopidogrel. |
| Clorazepic acid | Clorazepic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Clostridium | The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cisplatin. |
| Clotiazepam | The metabolism of Clotiazepam can be decreased when combined with Cisplatin. |
| Clove oil | Clove oil may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Clozapine | The risk or severity of neutropenia can be increased when Cisplatin is combined with Clozapine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Cocaine. |
| Colchicine | Colchicine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Colistimethate | Colistimethate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Colistin | Cisplatin may decrease the excretion rate of Colistin which could result in a higher serum level. |
| Conivaptan | Conivaptan may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Conjugated | Conjugated estrogens may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Corifollitropin alfa | Corifollitropin alfa may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Corticotropin | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Corticotropin. |
| Cortisone acetate | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Cortisone acetate. |
| Corynebacterium | The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cisplatin. |
| Crizotinib | The serum concentration of Cisplatin can be increased when it is combined with Crizotinib. |
| Cyanocobalamin | The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cisplatin. |
| Cyclopenthiazide | Cyclopenthiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Cyclophosphamide | The metabolism of Cyclophosphamide can be decreased when combined with Cisplatin. |
| Cyclosporine | Cisplatin may increase the immunosuppressive activities of Cyclosporine. |
| Cyclothiazide | Cyclothiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Cycrimine | The therapeutic efficacy of Cycrimine can be decreased when used in combination with Cisplatin. |
| Cyproheptadine | The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Cisplatin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Cytarabine. |
| Dabigatran | The risk or severity of bleeding can be increased when Dabigatran is combined with Cisplatin. |
| Dabigatran etexilate | Dabigatran etexilate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dabrafenib | The serum concentration of Cisplatin can be increased when it is combined with Dabrafenib. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Dacarbazine. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Dactinomycin. |
| Dalfampridine | The serum concentration of Dalfampridine can be increased when it is combined with Cisplatin. |
| Dalteparin | The risk or severity of bleeding can be increased when Dalteparin is combined with Cisplatin. |
| Danaparoid | The risk or severity of bleeding can be increased when Danaparoid is combined with Cisplatin. |
| Dapagliflozin | Dapagliflozin may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Daptomycin | Daptomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cisplatin. |
| Darifenacin | The therapeutic efficacy of Darifenacin can be decreased when used in combination with Cisplatin. |
| Dasatinib | The risk or severity of adverse effects can be increased when Cisplatin is combined with Dasatinib. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Daunorubicin. |
| Decitabine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Decitabine. |
| Deferiprone | Deferiprone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Defibrotide | The risk or severity of bleeding can be increased when Defibrotide is combined with Cisplatin. |
| Deflazacort | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Deflazacort. |
| Delafloxacin | Delafloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Cisplatin. |
| Desipramine | The serum concentration of Cisplatin can be increased when it is combined with Desipramine. |
| Desirudin | The risk or severity of bleeding can be increased when Desirudin is combined with Cisplatin. |
| Deslanoside | Deslanoside may decrease the cardiotoxic activities of Cisplatin. |
| Desloratadine | The therapeutic efficacy of Desloratadine can be decreased when used in combination with Cisplatin. |
| Desmopressin | Desmopressin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Desoximetasone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Desoximetasone. |
| Desvenlafaxine | Desvenlafaxine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Deucravacitinib | The risk or severity of adverse effects can be increased when Cisplatin is combined with Deucravacitinib. |
| Deutetrabenazine | Deutetrabenazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dexamethasone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Dexamethasone. |
| Dexamethasone acetate | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Dexamethasone acetate. |
| Dexchlorpheniramine | The serum concentration of Cisplatin can be increased when it is combined with Dexchlorpheniramine maleate. |
| Dexibuprofen | Dexibuprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dexketoprofen | Dexketoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dexmedetomidine | Dexmedetomidine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dexpanthenol | Dexpanthenol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cisplatin. |
| Dextran | Dextran may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dextromethorphan | The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Cisplatin. |
| Diatrizoate | Diatrizoate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Diazepam | Diazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dichlorobenzyl alcohol | Dichlorobenzyl alcohol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Diclofenac | Diclofenac may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Diclofenamide | Diclofenamide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Dicoumarol | The risk or severity of bleeding can be increased when Dicoumarol is combined with Cisplatin. |
| Dicyclomine | Dicyclomine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Didanosine | Didanosine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dienogest | Dienogest may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Diflunisal | Diflunisal may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Difluocortolone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Difluocortolone. |
| Digitoxin | Digitoxin may decrease the cardiotoxic activities of Cisplatin. |
| Digoxin | Cisplatin may decrease the excretion rate of Digoxin which could result in a higher serum level. |
| Dihydrostreptomycin | Dihydrostreptomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dimercaprol | Dimercaprol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Cisplatin is combined with Dimethyl fumarate. |
| Dimethyl sulfoxide | Dimethyl sulfoxide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dimetindene | The therapeutic efficacy of Dimetindene can be decreased when used in combination with Cisplatin. |
| Dinoprostone | The serum concentration of Cisplatin can be increased when it is combined with Dinoprostone. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Dinutuximab. |
| Diphemanil | The therapeutic efficacy of Diphemanil can be decreased when used in combination with Cisplatin. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Diphenhydramine. |
| Diphenidol | The therapeutic efficacy of Diphenidol can be decreased when used in combination with Cisplatin. |
| Dipyridamole | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Dipyridamole. |
| Diroximel fumarate | The risk or severity of adverse effects can be increased when Cisplatin is combined with Diroximel fumarate. |
| Disopyramide | The serum concentration of Cisplatin can be increased when it is combined with Disopyramide. |
| DL-Methylephedrine | DL-Methylephedrine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dobutamine | Dobutamine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Docetaxel | The risk or severity of adverse effects can be increased when Cisplatin is combined with Docetaxel. |
| Dofetilide | The serum concentration of Dofetilide can be increased when it is combined with Cisplatin. |
| Dolutegravir | The serum concentration of Cisplatin can be increased when it is combined with Dolutegravir. |
| Domperidone | The metabolism of Domperidone can be decreased when combined with Cisplatin. |
| Dopamine | The serum concentration of Cisplatin can be increased when it is combined with Dopamine. |
| Doripenem | Doripenem may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dosulepin | The metabolism of Dosulepin can be decreased when combined with Cisplatin. |
| Doxacurium | Doxacurium may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Doxepin | Doxepin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Doxorubicin. |
| Doxycycline | Doxycycline may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Doxylamine | The therapeutic efficacy of Doxylamine can be decreased when used in combination with Cisplatin. |
| Dronedarone | The serum concentration of Cisplatin can be increased when it is combined with Dronedarone. |
| Drospirenone | Drospirenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Drotrecogin alfa | The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cisplatin. |
| Droxidopa | Droxidopa may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Duloxetine | Duloxetine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Dyclonine. |
| Dyphylline | Dyphylline may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ebola Zaire vaccine | The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Cisplatin. |
| Eculizumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Eculizumab. |
| Edetic acid | The risk or severity of bleeding can be increased when Edetic acid is combined with Cisplatin. |
| Edoxaban | Edoxaban may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Edrophonium | Edrophonium may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Cisplatin. |
| Efavirenz | The metabolism of Efavirenz can be decreased when combined with Cisplatin. |
| Emapalumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Emapalumab. |
| Enalaprilat | Enalaprilat may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Enasidenib | The metabolism of Enasidenib can be decreased when combined with Cisplatin. |
| Enoxaparin | The risk or severity of bleeding can be increased when Enoxaparin is combined with Cisplatin. |
| Enzalutamide | Enzalutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ephedrine | Cisplatin may increase the neuromuscular blocking activities of Ephedrine. |
| Epinastine | The metabolism of Epinastine can be decreased when combined with Cisplatin. |
| Epinephrine | The serum concentration of Cisplatin can be increased when it is combined with Epinephrine. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Cisplatin. |
| Eplerenone | Eplerenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Epoprostenol | Epoprostenol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Eptifibatide | The risk or severity of bleeding can be increased when Eptifibatide is combined with Cisplatin. |
| Erdafitinib | The serum concentration of Cisplatin can be increased when it is combined with Erdafitinib. |
| Eribulin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Eribulin. |
| Ertapenem | Ertapenem may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ertugliflozin | Ertugliflozin may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cisplatin. |
| Escitalopram | The therapeutic efficacy of Escitalopram can be decreased when used in combination with Cisplatin. |
| Esketamine | The metabolism of Esketamine can be decreased when combined with Cisplatin. |
| Esmolol | Cisplatin may increase the bradycardic activities of Esmolol. |
| Estazolam | Estazolam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Estradiol | The serum concentration of Cisplatin can be increased when it is combined with Estradiol. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Cisplatin. |
| Ethambutol | Ethambutol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Etidocaine. |
| Etidronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Etidronic acid. |
| Etodolac | Etodolac may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Etomidate | Etomidate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Etonogestrel | Etonogestrel may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Etoposide | The risk or severity of adverse effects can be increased when Cisplatin is combined with Etoposide. |
| Etoricoxib | Etoricoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Eucalyptus oil | Eucalyptus oil may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Everolimus | The risk or severity of adverse effects can be increased when Cisplatin is combined with Everolimus. |
| Ezogabine | Ezogabine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Famotidine | The serum concentration of Cisplatin can be increased when it is combined with Famotidine. |
| Fenbufen | Fenbufen may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Fenfluramine | The metabolism of Fenfluramine can be decreased when combined with Cisplatin. |
| Fenofibrate | Fenofibrate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Fenofibric acid | Fenofibric acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Fenoldopam | Fenoldopam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Fenoprofen | Fenoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Fenoterol | The therapeutic efficacy of Fenoterol can be decreased when used in combination with Cisplatin. |
| Fentanyl | Fentanyl may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Fesoterodine | Fesoterodine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Fexinidazole | The serum concentration of Cisplatin can be increased when it is combined with Fexinidazole. |
| Filgotinib | The risk or severity of adverse effects can be increased when Cisplatin is combined with Filgotinib. |
| Finerenone | Finerenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Fingolimod | Cisplatin may increase the immunosuppressive activities of Fingolimod. |
| Flavoxate | Flavoxate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Floctafenine | Floctafenine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Florbetaben (18F) | Florbetaben (18F) may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Florbetapir (18F) | Florbetapir (18F) may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Cisplatin. |
| Fluconazole | Fluconazole may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Flucytosine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Flucytosine. |
| Fludarabine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Fludarabine. |
| Fludeoxyglucose (18F) | Fludeoxyglucose (18F) may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Fludrocortisone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fludrocortisone. |
| Fluindione | The risk or severity of bleeding can be increased when Fluindione is combined with Cisplatin. |
| Flumazenil | Flumazenil may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Flumethasone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Flumethasone. |
| Flunisolide | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Flunisolide. |
| Flunitrazepam | The metabolism of Flunitrazepam can be decreased when combined with Cisplatin. |
| Fluocinolone acetonide | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluocinolone acetonide. |
| Fluocinonide | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluocinonide. |
| Fluocortolone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluocortolone. |
| Fluorometholone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluorometholone. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Cisplatin is combined with Fluorouracil. |
| Fluoxetine | The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Cisplatin. |
| Flupentixol | The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cisplatin. |
| Fluprednisolone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluprednisolone. |
| Flurazepam | The serum concentration of Cisplatin can be increased when it is combined with Flurazepam. |
| Flurbiprofen | Flurbiprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Flutamide | Flutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Fluticasone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluticasone. |
| Fluticasone furoate | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluticasone furoate. |
| Fluticasone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluticasone propionate. |
| Fluvoxamine | Fluvoxamine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Folic acid | Folic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Fomepizole | Fomepizole may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Fondaparinux | Fondaparinux may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Formestane | Formestane may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Foscarnet | The risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Foscarnet. |
| Fosfomycin | Fosfomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Fosinopril | Fosinopril may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Fosphenytoin | Cisplatin can cause a decrease in the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Framycetin | Framycetin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Furosemide | Furosemide may increase the nephrotoxic and ototoxic activities of Cisplatin. |
| Gabapentin enacarbil | Gabapentin enacarbil may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Gadobenic acid | Gadobenic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Gadodiamide | Gadodiamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Gadofosveset trisodium | Gadofosveset trisodium may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Gadopentetic acid | Gadopentetic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Gadoteric acid | Gadoteric acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Gadoteridol | Gadoteridol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Gallamine | The therapeutic efficacy of Gallamine triethiodide can be decreased when used in combination with Cisplatin. |
| Gallium nitrate | The risk or severity of adverse effects can be increased when Cisplatin is combined with Gallium nitrate. |
| Ganciclovir | Ganciclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Cisplatin. |
| Gemfibrozil | Gemfibrozil may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cisplatin. |
| Gentamicin | The serum concentration of Gentamicin can be increased when it is combined with Cisplatin. |
| Gimeracil | Gimeracil may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Givosiran | Givosiran may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Glatiramer | The risk or severity of adverse effects can be increased when Cisplatin is combined with Glatiramer. |
| Glipizide | Glipizide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Glycerol phenylbutyrate | Glycerol phenylbutyrate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Glycopyrronium | The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Cisplatin. |
| Golimumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Golimumab. |
| Golodirsen | Golodirsen may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Goserelin | Goserelin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Grepafloxacin | The serum concentration of Cisplatin can be increased when it is combined with Grepafloxacin. |
| Guanethidine | Guanethidine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Haloperidol | Haloperidol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Halothane | The metabolism of Halothane can be decreased when combined with Cisplatin. |
| Heparin | The risk or severity of bleeding can be increased when Heparin is combined with Cisplatin. |
| Hepatitis A Vaccine | The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cisplatin. |
| Hepatitis B Vaccine | The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cisplatin. |
| Hexafluronium | The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Cisplatin. |
| Hexocyclium | The therapeutic efficacy of Hexocyclium can be decreased when used in combination with Cisplatin. |
| Histamine | The serum concentration of Cisplatin can be increased when it is combined with Histamine. |
| Homatropine | The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Cisplatin. |
| Human adenovirus | The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Cisplatin. |
| Hydralazine | Hydralazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Hydrochlorothiazide | Hydrochlorothiazide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Hydrocodone | The metabolism of Hydrocodone can be decreased when combined with Cisplatin. |
| Hydrocortisone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone. |
| Hydrocortisone acetate | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone acetate. |
| Hydrocortisone butyrate | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone butyrate. |
| Hydrocortisone cypionate | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone cypionate. |
| Hydrocortisone succinate | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone succinate. |
| Hydroflumethiazide | Hydroflumethiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Hydromorphone | Hydromorphone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Hydroxocobalamin | Hydroxocobalamin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Hydroxychloroquine. |
| Hydroxyethyl Starch | Hydroxyethyl Starch may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Cisplatin is combined with Hydroxyurea. |
| Hyoscyamine | The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Cisplatin. |
| Ibandronate | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Ibandronate. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cisplatin. |
| Ibrutinib | The risk or severity of adverse effects can be increased when Cisplatin is combined with Ibrutinib. |
| Ibuprofen | Ibuprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ibutilide | Ibutilide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Icatibant | Icatibant may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Icosapent | Icosapent may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Icosapent ethyl | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Cisplatin. |
| Idarubicin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Idarubicin. |
| Idarucizumab | Idarucizumab may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Idebenone | Idebenone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Idelalisib | The risk or severity of adverse effects can be increased when Cisplatin is combined with Idelalisib. |
| Ifosfamide | The metabolism of Ifosfamide can be decreased when combined with Cisplatin. |
| Iloprost | The risk or severity of bleeding can be increased when Iloprost is combined with Cisplatin. |
| Imatinib | The risk or severity of adverse effects can be increased when Cisplatin is combined with Imatinib. |
| Imipramine | The serum concentration of Cisplatin can be increased when it is combined with Imipramine. |
| Indapamide | Indapamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Indigotindisulfonic acid | Indigotindisulfonic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Cisplatin. |
| Inebilizumab | The risk or severity of infection can be increased when Cisplatin is combined with Inebilizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Cisplatin. |
| Ketoprofen | Ketoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ketorolac | Ketorolac may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Labetalol | Labetalol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Lamivudine | Lamivudine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Lamotrigine | The serum concentration of Cisplatin can be increased when it is combined with Lamotrigine. |
| Latamoxef | Latamoxef may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ledipasvir | Ledipasvir may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Leflunomide | The risk or severity of adverse effects can be increased when Cisplatin is combined with Leflunomide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Cisplatin. |
| Lenvatinib | The serum concentration of Cisplatin can be increased when it is combined with Lenvatinib. |
| Lepirudin | The risk or severity of bleeding can be increased when Lepirudin is combined with Cisplatin. |
| Lesinurad | Lesinurad may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Leuprolide | Leuprolide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Levacetylmethadol | The therapeutic efficacy of Levacetylmethadol can be decreased when used in combination with Cisplatin. |
| Levobetaxolol | Cisplatin may increase the bradycardic activities of Levobetaxolol. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Levobupivacaine. |
| Levocarnitine | Levocarnitine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Levocetirizine | Levocetirizine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Levofloxacin | Levofloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Levoketoconazole | The serum concentration of Cisplatin can be increased when it is combined with Levoketoconazole. |
| Levomilnacipran | Levomilnacipran may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Levosalbutamol | Levosalbutamol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Lidocaine. |
| Linagliptin | The serum concentration of Cisplatin can be increased when it is combined with Linagliptin. |
| Linezolid | The risk or severity of adverse effects can be increased when Cisplatin is combined with Linezolid. |
| Liothyronine | Liothyronine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Lipegfilgrastim | Cisplatin may increase the myelosuppressive activities of Lipegfilgrastim. |
| Lipoic acid | The risk or severity of cytotoxicity can be decreased when Lipoic acid is combined with Cisplatin. |
| Lisinopril | Lisinopril may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Lithium carbonate | Cisplatin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. |
| Lithium citrate | Lithium citrate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Lixisenatide | Lixisenatide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Lofexidine | Lofexidine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Lomustine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Lomustine. |
| Lopinavir | The serum concentration of Cisplatin can be increased when it is combined with Lopinavir. |
| Loracarbef | Loracarbef may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Lorazepam | Lorazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Lorcaserin | Lorcaserin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Lornoxicam | Lornoxicam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Lorpiprazole | Lorpiprazole may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Loxoprofen | Loxoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Lubiprostone | Lubiprostone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Lumiracoxib | Lumiracoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Macitentan | Macitentan may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Cisplatin. |
| Magnesium carbonate | Magnesium carbonate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Magnesium chloride | Magnesium chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Magnesium hydroxide | Magnesium hydroxide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Magnesium trisilicate | Magnesium trisilicate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Mangafodipir | Mangafodipir may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Mannitol | The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cisplatin. |
| Maprotiline | Maprotiline may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Measles virus vaccine | The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Cisplatin. |
| Mebeverine | The therapeutic efficacy of Mebeverine can be decreased when used in combination with Cisplatin. |
| Mecamylamine | Mecamylamine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Mechlorethamine. |
| Meclizine | The therapeutic efficacy of Meclizine can be decreased when used in combination with Cisplatin. |
| Meclofenamic acid | Meclofenamic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Medroxyprogesterone | Medroxyprogesterone acetate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Mefenamic acid | Mefenamic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Megestrol acetate | Megestrol acetate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Meloxicam. |
| Melphalan | The risk or severity of adverse effects can be increased when Cisplatin is combined with Melphalan. |
| Memantine | Memantine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Meningococcal | The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Cisplatin. |
| Mepenzolate | The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Cisplatin. |
| Meperidine | Meperidine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Mephenytoin | The metabolism of Mephenytoin can be decreased when combined with Cisplatin. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Mepivacaine. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Mepolizumab. |
| Meprednisone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Meprednisone. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Mercaptopurine. |
| Meropenem | Meropenem may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Mesalazine | Mesalazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Metamfetamine | Metamfetamine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Metamizole | Metamizole may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Metaxalone | Metaxalone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Methacholine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Methacholine. |
| Methadone | Methadone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Methantheline | The therapeutic efficacy of Methantheline can be decreased when used in combination with Cisplatin. |
| Methazolamide | Methazolamide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Methimazole | The risk or severity of adverse effects can be increased when Cisplatin is combined with Methimazole. |
| Methotrexate | The risk or severity of adverse effects can be increased when Cisplatin is combined with Methotrexate. |
| Methotrimeprazine | The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Cisplatin. |
| Methoxsalen | Methoxsalen may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Methoxy polyethylene | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cisplatin. |
| Methoxyflurane | The metabolism of Methoxyflurane can be decreased when combined with Cisplatin. |
| Methscopolamine | The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Cisplatin. |
| Methscopolamine | The therapeutic efficacy of Methscopolamine bromide can be decreased when used in combination with Cisplatin. |
| Methyldopa | Methyldopa may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Methylene blue | The serum concentration of Cisplatin can be increased when it is combined with Methylene blue. |
| Methylnaltrexone | Methylnaltrexone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Methylphenobarbital | The metabolism of Methylphenobarbital can be decreased when combined with Cisplatin. |
| Methylprednisolone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Methylprednisolone. |
| Methylprednisolone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Methylprednisolone aceponate. |
| Methylprednisolone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Methylprednisolone hemisuccinate. |
| Methyltestosterone | Methyltestosterone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Cisplatin. |
| Muzolimine | Muzolimine may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Cisplatin is combined with Mycophenolate mofetil. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Cisplatin is combined with Mycophenolic acid. |
| N-acetyltyrosine | N-acetyltyrosine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Nabumetone | Nabumetone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Nadolol | Nadolol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Nadroparin | The risk or severity of bleeding can be increased when Nadroparin is combined with Cisplatin. |
| Naldemedine | Naldemedine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Nalmefene | Nalmefene may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Naloxone | Naloxone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Naproxen | Naproxen may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Natalizumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Natalizumab. |
| Nateglinide | Nateglinide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Nebivolol | Cisplatin may increase the bradycardic activities of Nebivolol. |
| Nedaplatin | Cisplatin may decrease the excretion rate of Nedaplatin which could result in a higher serum level. |
| Nedocromil | Nedocromil may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Nefazodone | Nefazodone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Nelarabine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Nelarabine. |
| Neomycin | The risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Neomycin. |
| Netilmicin | Cisplatin may decrease the excretion rate of Netilmicin which could result in a higher serum level. |
| Nevirapine | The metabolism of Nevirapine can be decreased when combined with Cisplatin. |
| Nicardipine | The therapeutic efficacy of Nicardipine can be decreased when used in combination with Cisplatin. |
| Nicorandil | Nicorandil may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Nicotine | The serum concentration of Cisplatin can be increased when it is combined with Nicotine. |
| Nifedipine | Nifedipine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Nilotinib | The risk or severity of adverse effects can be increased when Cisplatin is combined with Nilotinib. |
| Nilutamide | Nilutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Nimesulide | Nimesulide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Nisoldipine | Nisoldipine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Nitric Oxide | Nitric Oxide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Nitrofurantoin | Nitrofurantoin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Nitroprusside | Nitroprusside may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Norepinephrine | The serum concentration of Cisplatin can be increased when it is combined with Norepinephrine. |
| Norgestimate | The metabolism of Norgestimate can be decreased when combined with Cisplatin. |
| Nortriptyline | The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Cisplatin. |
| Nuvaxovid | The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Cisplatin. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Obinutuzumab. |
| Ocrelizumab | Ocrelizumab may increase the immunosuppressive activities of Cisplatin. |
| Octinoxate | Octinoxate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ofatumumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Ofatumumab. |
| Olanzapine | The therapeutic efficacy of Olanzapine can be decreased when used in combination with Cisplatin. |
| Olaparib | The risk or severity of adverse effects can be increased when Cisplatin is combined with Olaparib. |
| Olsalazine | Olsalazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Opium | Opium may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Orphenadrine | The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Cisplatin. |
| Oseltamivir | Oseltamivir may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Osilodrostat | The metabolism of Osilodrostat can be decreased when combined with Cisplatin. |
| Ospemifene | The metabolism of Ospemifene can be decreased when combined with Cisplatin. |
| Ouabain | Ouabain may decrease the cardiotoxic activities of Cisplatin. |
| Oxacillin | Oxacillin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Oxaliplatin. |
| Oxaprozin | Oxaprozin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Oxazepam | Oxazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Oxetacaine. |
| Oxprenolol | The serum concentration of Cisplatin can be increased when it is combined with Oxprenolol. |
| Oxybenzone | Oxybenzone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Oxybuprocaine. |
| Oxybutynin | The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Cisplatin. |
| Oxyphenbutazone | Oxyphenbutazone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Oxyphencyclimine | The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Cisplatin. |
| Oxyphenonium | The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Cisplatin. |
| Oxyquinoline | Oxyquinoline may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ozanimod | The risk or severity of adverse effects can be increased when Cisplatin is combined with Ozanimod. |
| Paclitaxel | The risk or severity of adverse effects can be increased when Cisplatin is combined with Paclitaxel. |
| Palbociclib | The risk or severity of adverse effects can be increased when Cisplatin is combined with Palbociclib. |
| Palifermin | The therapeutic efficacy of Palifermin can be decreased when used in combination with Cisplatin. |
| Paliperidone | Paliperidone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Palonosetron | Palonosetron may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Pamidronic acid | Pamidronic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be decreased when used in combination with Cisplatin. |
| Panobinostat | The risk or severity of adverse effects can be increased when Cisplatin is combined with Panobinostat. |
| Pantoprazole | Pantoprazole may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ranitidine | The serum concentration of Cisplatin can be increased when it is combined with Ranitidine. |
| Ranolazine | The serum concentration of Cisplatin can be increased when it is combined with Ranolazine. |
| Rapacuronium | The therapeutic efficacy of Rapacuronium can be decreased when used in combination with Cisplatin. |
| Rasagiline | Rasagiline may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ravulizumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Ravulizumab. |
| Reserpine | Reserpine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Resorcinol | Resorcinol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Reteplase | The risk or severity of bleeding can be increased when Reteplase is combined with Cisplatin. |
| Revefenacin | The therapeutic efficacy of Revefenacin can be decreased when used in combination with Cisplatin. |
| Reviparin | The risk or severity of bleeding can be increased when Reviparin is combined with Cisplatin. |
| Ribavirin | Ribavirin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Ribostamycin | Cisplatin may decrease the excretion rate of Ribostamycin which could result in a higher serum level. |
| Rilonacept | The risk or severity of adverse effects can be increased when Cisplatin is combined with Rilonacept. |
| Risankizumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Risankizumab. |
| Risedronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Risedronic acid. |
| Rituximab | Rituximab may increase the nephrotoxic activities of Cisplatin. |
| Rivaroxaban | Rivaroxaban may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Rizatriptan | Rizatriptan may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Rocuronium | The therapeutic efficacy of Rocuronium can be decreased when used in combination with Cisplatin. |
| Rofecoxib | Rofecoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Roflumilast | Roflumilast may increase the immunosuppressive activities of Cisplatin. |
| Romidepsin | The metabolism of Romidepsin can be decreased when combined with Cisplatin. |
| Ropeginterferon alfa-2b | The risk or severity of adverse effects can be increased when Cisplatin is combined with Ropeginterferon alfa-2b. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Ropivacaine. |
| Rosiglitazone | Rosiglitazone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Rotavirus vaccine | The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Cisplatin. |
| Rubella virus vaccine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Cisplatin. |
| Ruxolitinib | The risk or severity of adverse effects can be increased when Cisplatin is combined with Ruxolitinib. |
| Sacubitril | Sacubitril may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Salbutamol | Salbutamol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Salicylamide | Salicylamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Salicylic acid | Salicylic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Salmeterol | The risk or severity of hypokalemia can be increased when Cisplatin is combined with Salmeterol. |
| Salmon calcitonin | Salmon calcitonin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Salsalate | Salsalate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Sarilumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Sarilumab. |
| Satralizumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Satralizumab. |
| Saxagliptin | Saxagliptin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Scopolamine | The therapeutic efficacy of Scopolamine can be decreased when used in combination with Cisplatin. |
| Secobarbital | Secobarbital may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Secukinumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Secukinumab. |
| Selegiline | The metabolism of Selegiline can be decreased when combined with Cisplatin. |
| Selenious acid | Selenious acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Selenium | Selenium may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Sevoflurane | The metabolism of Sevoflurane can be decreased when combined with Cisplatin. |
| Sibutramine | Sibutramine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Siltuximab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Siltuximab. |
| Siponimod | The risk or severity of adverse effects can be increased when Cisplatin is combined with Siponimod. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cisplatin. |
| Sirolimus | The risk or severity of adverse effects can be increased when Cisplatin is combined with Sirolimus. |
| Sitagliptin | Sitagliptin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Smallpox (Vaccinia) | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Cisplatin. |
| Sodium acetate | Sodium acetate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Sodium aurothiomalate | Sodium aurothiomalate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Sodium bisulfite | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Sodium bisulfite. |
| Sodium citrate | The risk or severity of bleeding can be increased when Sodium citrate is combined with Cisplatin. |
| Sodium fluoride | Sodium fluoride may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Sodium sulfate | Sodium sulfate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Sofosbuvir | Sofosbuvir may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Solifenacin | The therapeutic efficacy of Solifenacin can be decreased when used in combination with Cisplatin. |
| Solriamfetol | Solriamfetol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Cisplatin. |
| Sorbitol | Sorbitol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Sotalol | Cisplatin may increase the bradycardic activities of Sotalol. |
| Spesolimab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Spesolimab. |
| Spironolactone | Spironolactone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Stiripentol | Stiripentol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Streptokinase | The risk or severity of bleeding can be increased when Streptokinase is combined with Cisplatin. |
| Streptomycin | Cisplatin may decrease the excretion rate of Streptomycin which could result in a higher serum level. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Cisplatin. |
| Strontium chloride | Strontium chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Succinylcholine | The metabolism of Succinylcholine can be decreased when combined with Cisplatin. |
| Sucralfate | Sucralfate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Sulbactam | Sulbactam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Sulfadiazine | Sulfadiazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Sulfamethoxazole | The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cisplatin. |
| Zonisamide | Zonisamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Zoledronic acid | The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Zoledronic acid. |
| Ziprasidone | The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Cisplatin. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Cisplatin. |
| Zanubrutinib | The metabolism of Zanubrutinib can be decreased when combined with Cisplatin. |
| Zanamivir | Zanamivir may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Zaleplon | Zaleplon may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Yellow fever vaccine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Cisplatin. |
| Ximelagatran | The risk or severity of bleeding can be increased when Ximelagatran is combined with Cisplatin. |
| Warfarin | Cisplatin may decrease the excretion rate of Warfarin which could result in a higher serum level. |
| Voxelotor | The metabolism of Voxelotor can be decreased when combined with Cisplatin. |
| Vortioxetine | Vortioxetine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Vorinostat | The risk or severity of adverse effects can be increased when Cisplatin is combined with Vorinostat. |
| Vorapaxar | The risk or severity of bleeding can be increased when Vorapaxar is combined with Cisplatin. |
| Voclosporin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Voclosporin. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Vinorelbine. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Cisplatin. |
| Vincristine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Vincristine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Vinblastine. |
| Viloxazine | Viloxazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Vilanterol | The risk or severity of adverse effects can be increased when Cisplatin is combined with Vilanterol. |
| Vibrio cholerae | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cisplatin. |
| Verapamil | Verapamil may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Venlafaxine | Venlafaxine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Velpatasvir | The metabolism of Velpatasvir can be decreased when combined with Cisplatin. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Vedolizumab. |
| Vecuronium | The therapeutic efficacy of Vecuronium can be decreased when used in combination with Cisplatin. |
| Varicella zoster vaccine | The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Cisplatin. |
| Varicella zoster vaccine | The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Cisplatin. |
| Varenicline | The excretion of Varenicline can be decreased when combined with Cisplatin. |
| Vandetanib | The serum concentration of Cisplatin can be increased when it is combined with Vandetanib. |
| Vancomycin | Vancomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Valproic acid | The metabolism of Valproic acid can be decreased when combined with Cisplatin. |
| Valganciclovir | Valganciclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Valdecoxib | Valdecoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Valbenazine | Valbenazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Valaciclovir | Valaciclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Vaborbactam | Vaborbactam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Urokinase | The risk or severity of bleeding can be increased when Urokinase is combined with Cisplatin. |
| Upadacitinib | The risk or severity of adverse effects can be increased when Cisplatin is combined with Upadacitinib. |
| Umeclidinium | The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Cisplatin. |
| Typhoid Vi | The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Cisplatin. |
| Typhoid Vaccine Live | The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Cisplatin. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Cisplatin. |
| Tucatinib | The serum concentration of Cisplatin can be increased when it is combined with Tucatinib. |
| Tubocurarine | Cisplatin may increase the neuromuscular blocking activities of Tubocurarine. |
| Trospium | The therapeutic efficacy of Trospium can be decreased when used in combination with Cisplatin. |
| Tropisetron | Tropisetron may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Trimetrexate | Trimetrexate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Trimethoprim | The serum concentration of Cisplatin can be increased when it is combined with Trimethoprim. |
| Trimethaphan | Cisplatin may increase the neuromuscular blocking activities of Trimethaphan. |
| Trimebutine | Trimebutine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Trilostane | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Trilostane. |
| Trilaciclib | The risk or severity of nephrotoxicity can be increased when Trilaciclib is combined with Cisplatin. |
| Trihexyphenidyl | The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Cisplatin. |
| Triflusal | The risk or severity of bleeding can be increased when Triflusal is combined with Cisplatin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Cisplatin. |
| Triflupromazine | The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Cisplatin. |
| Triethylenetetramine | Triethylenetetramine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Trichlormethiazide | Trichlormethiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Triazolam | Triazolam may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Triamterene | Triamterene may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Triamcinolone | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Triamcinolone. |
| Tretinoin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Tretinoin. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Cisplatin is combined with Trastuzumab emtansine. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Cisplatin. |
| Trametinib | Trametinib may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Tramadol | Tramadol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Trabectedin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Trabectedin. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Cisplatin. |
| Torasemide | The risk or severity of ototoxicity and nephrotoxicity can be increased when Torasemide is combined with Cisplatin. |
| Topotecan | The risk or severity of adverse effects can be increased when Cisplatin is combined with Topotecan. |
| Topiramate | Topiramate may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Tolvaptan | Tolvaptan may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. |
| Tolterodine | Tolterodine may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Tolmetin | Tolmetin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Tolfenamic acid | Tolfenamic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Tolcapone | Tolcapone may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Tolbutamide | Tolbutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Tolazamide | Tolazamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Tofacitinib | Cisplatin may increase the immunosuppressive activities of Tofacitinib. |
| Tocopherol | Tocopherol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Tocilizumab | The risk or severity of adverse effects can be increased when Cisplatin is combined with Tocilizumab. |
| Tobramycin | Cisplatin may decrease the excretion rate of Tobramycin which could result in a higher serum level. |
| Tixocortol | The therapeutic efficacy of Cisplatin can be decreased when used in combination with Tixocortol. |
| Tirofiban | Tirofiban may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Tipiracil | The excretion of Tipiracil can be decreased when combined with Cisplatin. |
| Tiotropium | Tiotropium may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Tiopronin | Tiopronin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Cisplatin. |
| Tinzaparin | The risk or severity of bleeding can be increased when Tinzaparin is combined with Cisplatin. |
| Tinidazole | Tinidazole may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Timolol | Timolol may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
| Tiludronic acid | Tiludronic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
Pregnancy and Lactation
FDA Pregnancy category D
Pregnancy
There is a possibility of birth defects if either the man or woman is using cisplatin at the time of conception, or if it is taken during pregnancy. This medication should not be used during pregnancy unless the benefits outweigh the risks. Use effective birth control while you are being treated with this medication. If you become pregnant while taking this medication, contact your doctor immediately.
Breast-feeding
This medication passes into breast milk. Women receiving this medication should not breastfeed.
How should this medicine be used?
Cisplatin injection comes as a solution (liquid) to be injected over 6 to 8 hours intravenously (into a vein) by a doctor or nurse in a medical facility. It is usually given once every 3 to 4 weeks.
What special precautions should I follow?
Before taking cisplatin,
- tell your doctor and pharmacist if you are allergic to cisplatin, carboplatin (Paraplatin), any other medications, or any of the ingredients in cisplatin injection. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the medications listed in the IMPORTANT WARNING section and any of the following: amphotericin B (Abelcet; AmBisome; Amphotec, Fungizone Intravenous), anticonvulsants such as phenytoin (Dilantin), bumetanide (Bumex), ethacrynic acid (Edecrin), furosemide (Lasix), pyridoxine (Vitamin B-6). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with cisplatin, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- tell your doctor if you have kidney disease or hearing problems. Your doctor may not want you to receive cisplatin injection.
- tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. You should not become pregnant or breast-feed while you are receiving cisplatin. If you become pregnant while receiving cisplatin, call your doctor. Cisplatin may harm the fetus.
Before you begin using a medication, be sure to inform your doctor of any medical conditions or allergies you may have, any medications you are taking, whether you are pregnant or breastfeeding, and any other significant facts about your health. These factors may affect how you should use this medication.
Blood clotting: This medication can reduce the number of platelet cells in the blood and increase your risk of bleeding. Tell your doctor immediately if you notice any signs that your blood is not clotting as quickly as usual (e.g., black and tarry stools, blood in the urine, easy bruising, or cuts that won’t stop bleeding). Your doctor will do blood tests regularly to monitor the number of platelets in your blood.
Gout: This medication may cause high levels of uric acid in the blood, making gout more likely to occur. If you have gout or a history of gout, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed. Report any unusual joint pain or swelling to your doctor as soon as possible.
Hearing impairment: This medication can cause permanent hearing damage and should not be given to anyone with hearing impairment. Your hearing will be monitored closely while you are using this medication.
Infection: In addition to killing cancer cells, this medication can reduce the number of cells that fight infection in the body (white blood cells). If possible, avoid contact with people with contagious infections. Tell your doctor immediately if you notice signs of an infection, such as fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness. Your doctor will do blood tests regularly to monitor the number of specific types of blood cells in your blood.
Kidney function: Cisplatin can reduce kidney function and cause kidney damage. For this reason, it is very important to drink plenty of fluids right after your treatment. Your doctor may want you to drink extra fluids while taking this medication in order to help you pass more fluid and protect your kidneys. Your doctor will monitor your kidney function closely while you are using this medication. If you have reduced kidney function you should not use this medication.
Nervous system: Cisplatin can cause damage to the nervous system. If you experience symptoms such as loss of taste, tingling in the hands or feet, or balance trouble, tell your doctor as soon as possible. These side effects are often reversible if the medication is stopped early.
References
